Oculis Holding AG is a late clinical stage biopharmaceutical company specializing in novel therapeutics to treat ophthalmic, neuro-ophthalmic, and neurological diseases. Founded in October 2003 and incorporated as Oculis SA in December 2017, the company has no approved products. Its pipeline includes OCS-01, Licaminlimab (OCS-02), and Privosegtor (OCS-05), targeting multiple ophthalmic diseases. It has not generated product revenue and relies on third-party manufacturers for clinical drug supplies.
48 total filings indexed. 48 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001953530 |
| Ticker | OCS |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | V8 |
| Website | https://www.oculis.com |
| Listed | 2023-03-03 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/OCS (~200 tokens, structured JSON with cryptographic provenance)